Waystar Weighs Sale as Shares Slide Amid Software Sector Downturn

In a strategic move, healthcare software company Waystar is reportedly exploring a possible sale just two years after going public. The company, which operates from Lehi, Utah, and Louisville, Kentucky, has engaged investment bank Evercore to guide the process, according to several sources familiar with the matter. The discussions are still in preliminary stages, and a sale is not guaranteed, these sources added.

Waystar's decision to consider selling comes amid a significant drop in its market valuation, now approximately $4.8 billion following a 24% decline in its share price this year. This downturn reflects a broader selloff affecting the software sector. The company's management is assessing whether investor interest in software enterprises is rebounding, potentially influencing the outcome of any auction process.

Strategic Positioning and Market Challenges

Waystar has positioned itself distinctly as a technology firm focused on automating administrative tasks for healthcare providers, distancing itself from traditional healthcare services that rely heavily on human resources. This approach was intended to secure higher valuations typical of technology companies. Initially, this strategy found favor with investors, propelling the company's stock from $20 to a peak of $45 in 2025. However, recent apprehensions about potential disruptions from advancements in artificial intelligence have pressured the stock, as noted by Morgan Stanley analysts in a report from July.

The company emerged from the 2017 merger of Zirmed and Navicure, both healthcare revenue management firms. Its primary investors include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, which collectively took Waystar public in 2024. EQT remains the largest shareholder with a 13% stake, followed by CPPIB with 10%, and BlackRock Institutional Trust Company with an 8% share, according to data from LSEG.

Current Market Environment

Waystar's exploration of a sale reflects broader market dynamics, as software companies face increasing scrutiny and market volatility. The potential transaction could gauge whether the investment climate is becoming more favorable for software businesses. Waystar's move signals a strategic reevaluation as it navigates these challenges. Both EQT and CPPIB have not commented on the potential sale, while BlackRock also declined to comment.

The outcome of Waystar's exploration remains uncertain, yet it underscores the shifting landscape for tech-driven healthcare solutions amid evolving investor sentiment and technological advancements.